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Abstract
Background: Non-small cell lung cancer (NSCLC) is the leading cause of cancer mortality
worldwide. At present no reliable biomarkers are available to guide the management of this
condition. Microarray technology may allow appropriate biomarkers to be identified but present
platforms are lacking disease focus and are thus likely to miss potentially vital information contained
in patient tissue samples.
Methods: A combination of large-scale in-house sequencing, gene expression profiling and public
sequence and gene expression data mining were used to characterise the transcriptome of NSCLC
and the data used to generate a disease-focused microarray – the Lung Cancer DSA research tool.
Results: Built on the Affymetrix GeneChip platform, the Lung Cancer DSA research tool allows
for interrogation of ~60,000 transcripts relevant to Lung Cancer, tens of thousands of which are
unavailable on leading commercial microarrays.
Conclusion: We have developed the first high-density disease specific transcriptome microarray.
We present the array design process and the results of experiments carried out to demonstrate
the array's utility. This approach serves as a template for the development of other disease
transcriptome microarrays, including non-neoplastic diseases.
Background
Lung cancer is the single largest cause of cancer mortality
worldwide [1]. The majority of lung cancer cases (70–
85%) are non-small cell lung carcinoma (NSCLC), charac-
terised by low treatment response rates and poor overall
prognosis with 5-year survival of 15% and survival rate
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ease is critical for the identification of the best treatment
modalities and means of managing the disease [3]. How-
ever, the standard Tumour, Nodes, Metastasis (TNM) sys-
tem used by pathologists in this respect is imprecise and
limited information on prognosis [4] and the potential
benefit from adjuvant or neo-adjuvant chemotherapy.
In recent years there has been an increasing focus on
understanding the molecular basis of NSCLC [5]. A
number of genes including p53, RRM1 and ERCC1 have
been identified as being important in the development
and progression of NSCLC [6,7]. A cluster of tumour sup-
pressor genes at region 3p21.3 have been indicated as
inhibiting growth of lung cancer cells, and deletions in
this region are commonly seen in lung and other cancers
[8,9]. Other studies have examined the utility of molecu-
lar markers like EGFR and HER2 status in predicting
patient survival and response to chemotherapy [1,10-12]
and suggested that NSCLC is a prime candidate for tar-
geted/individualised therapy [13-16].
Recent developments in the field of molecular genetics
have highlighted the complexity of the transcriptome,
questioning many of the fundamental assumptions about
genes and their regulation [17-20]. This complexity is pri-
marily due to processes such as the alternative splicing
and polyadenylation of coding transcripts and the pres-
ence of non-coding and antisense transcripts, with non-
coding transcripts thought to make up a substantial pro-
portion of the human transcriptome [21,22]. The mam-
malian transcriptome has been estimated to consist of as
many as 107 RNAs [23] and it has been suggested that the
transcript rather than the gene should be regarded as the
operational unit of the genome [24]. This is of particular
relevance to lung tissue, which has been shown to have a
high degree of transcriptome complexity relative to other
tissues [25,26].
Commonly used gene expression profiling tools are sub-
optimal for the study of lung tissue as they focus on well-
characterized genes, resulting in the omission of a signifi-
cant amount of information potentially of biological
importance within the lung transcriptome. An expression
array capable of detecting the entire human transcriptome
would yield substantial benefits; however, this is unach-
ievable with the current capacity limitations of microarray
technology.
Therefore, focusing on the generation of gene expression
arrays comprehensively representing the transcriptomes
of individual tissues and diseases is a more feasible
approach with current technology platforms. Using this
approach we have characterized the transcriptome of
Non-Small Cell Lung Carcinoma (NSCLC) and normal
lung tissue and used this information to develop a disease
focused microarray – the Lung Cancer DSA research tool.
We believe that this platform enables comprehensive tran-





The NSCLC tumor libraries were generated from a set of
frozen tissue samples including ~60% adenocarcinomas
and ~40% squamous cell carcinomas and representing all
TNM stages, derived from 65 male and female patients.
The normal library was generated from a set of frozen nor-
mal lung tissues obtained from 19 male and female
donors representing a mix of ethnicities and an age range
of 32–65 years. All samples were collected following con-
sultation with the University of Liverpool Committee on
Research Ethics and with the written consent of all partic-
ipating patients.
Samples of frozen lung tissue were homogenized in RNA
STAT-60 (Tel-Test), and RNA was extracted according to
the manufacturer's instructions. Equal amounts of good
quality total RNAs were pooled and mRNA was isolated
using the μMACS mRNA isolation kit (Miltenyi Biotec) as
described by the manufacturer. Non-radiolabeled lung
cDNA libraries were constructed from 3 μg of mRNA
using the CloneMiner™ cDNA library construction kit
(Invitrogen) according to manufacturer's instructions. The
titer and average insert size in each cDNA library was
determined according to the manufacturer's instructions
and plasmid preparations of individual clones were car-
ried out using a modified Montáge® alkaline lysis method
(Millipore) that incorporates MultiScreen® Plasmid384
Miniprep clearing plates for centrifugal lysate clearing.
Sequencing of lung cDNA libraries
Cycle sequencing reactions were performed in 10 μl vol-
umes using a 1/16 dilution of Big Dye Terminator v3.1
ready reaction mix in Big Dye sequencing buffer (Applied
Biosystems Inc.), 5 μM M13 primer and 100 ng template
DNA. Cycle sequencing was performed for 40 cycles at
95°C for 10 sec; 50°C for 5 sec and 60°C for 2 min 30 sec.
Excess dye terminators were removed using CleanSEQ
(Agencourt Biosciences). Sequence plates were analyzed
on Applied Biosystems 3730/3730 × l DNA Analyzers
using Applied Biosystems Sequence Analysis software.
Retrieval of public lung sequences
Human lung EST libraries were retrieved using the cDNA
Library Finder at the National Cancer Institute's Cancer
Genome Anatomy Project (CGAP) [27] website [28] (All
cDNA libraries were retrieved from the CGAP website.Page 2 of 12
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excluded.
Inclusion of gene expression data
A total of 870 annotated microarray profiles generated on
HG-U133 Plus 2 arrays were retrieved from the Interna-
tional Genomics Consortium (expO) website [29] and
processed using custom Perl scripts. 60 profiles originat-
ing from lung cancer samples were identified and
probesets called present by the Affymetrix MAS5 algo-
rithm in ≥ 10% of those were selected. In-house expres-
sion profiling of 5 normal and 5 tumor lung frozen
samples was performed on HG-U133 Plus 2 arrays using
standard Affymetrix protocols. Profiles were screened for
MAS5 present calls and probesets called present at least
once were combined with the probesets selected from
expO data. Full-length sequences corresponding to the
selected Affymetrix probeset identifiers were downloaded
from the Affymetrix website [30] and separated into poly-
adenylated and non-polyadenylated sequence groupings
using Paracel Filtering Package.
Literature mining
A non-redundant list of genes previously associated with
lung cancer was composed by means of Pubmed searches,
subsequent literature review and by use of GeneGO's Met-
acore curated knowledgebase [31]. IDs of literature-
derived genes were used to retrieve corresponding full-
length mRNA sequences from the RefSeq [32,33], EMBL
nucleotide sequence [34,35] and Ensembl [36] databases.
The complete antisense complements to retrieved
sequences were generated computationally.
Processing of public and in-house sequences
The 5' ESTs were filtered using Paracel Filtering Package
(Paracel Inc.). Mitochondrial, bacterial and ribosomal
contaminants as well as vector sequences, polyA tails,
ambiguous end-regions and ESTs shorter than 100-bases
were removed. Masking was performed for low-complex-
ity regions (LCRs) and repeat sequences. The 3' ESTs were
converted in to sense orientation using SeqUtil (Paracel
Inc.) and filtered similarly to 5' ESTs, except 3' ESTs not
containing polyA tails (8 or more consecutive adenine
bases) were removed and masking of repeat sequences
and LCRs was not performed in order to facilitate subse-
quent identification of alternative polyadenylation.
Paracel Transcript Assembler (PTA) (Paracel Inc.), a mod-
ified version of the CAP3 program [37] was used with
default settings to assemble filtered 5' ESTs. The filtered 3'
ESTs were also assembled using PTA but with the
sequence-clipping option disabled and annotation of
LCRs and repeats enabled in order to prevent spurious
clustering and modification of the input sequences and to
facilitate subsequent identification of alternative polyade-
nylation.
Detection of internal priming in 3' contigs and singlets
3' derived contigs and singlets were BLASTed against the
RefSeq and EMBL databases. All BLAST analyses reported
here were performed using Paracel Blast with e-value <
0.1. BLAST results and sequence files were processed using
custom Perl scripts. Only same orientation alignments
with sequence identity ≥ 95% over at least 100 bp (80 bp
for singlets) and with <5 mismatches at their 3' extremity
were considered. Alignment end-points (i.e. the last target
base position matching the query sequence) were deter-
mined. Multiple alignment end-points occurring within a
300 bp window were clustered to produce a single end-
point. The regions of target database sequences immedi-
ately downstream of the alignment end-points were ana-
lyzed for the presence of potential internal priming sites
i.e. 8 or more adenine bases in a 10-base window.
Detection of alternative polyadenylation in contigs derived from 3' 
sequencing
All 3' ESTs used in the assembly were BLASTed against the
contigs resulting from the assembly. Only same orienta-
tion alignments with sequence identity ≥ 95% and <26
mismatches at the 5' extremity and <5 mismatches at the
3' extremity of the query sequence were considered. Align-
ment end-points were determined and multiple end-
points within a 300 bp window were clustered to produce
a single end-point. Alignments ending <300 bp from a
contig's 3' end were disregarded. The contig regions
immediately downstream of the end-points were ana-
lyzed for the presence of potential internal priming sites
and disregarded if internal priming appeared likely. Oth-
erwise contigs were cleaved to produce alternatively poly-
adenylated forms.
3'extension of sequences
Completeness of 3' coverage was uncertain for contigs
derived from the 5' EST assembly and for non-polyade-
nylated sequences derived from expression data. In order
to ensure proximity to a polyA tail and compatibility with
3' biased RNA amplification and labelling protocols an
attempt was made to extend these sequences by aligning
them to sequences from public databases. Where contig
sequences could be extended in the same orientation, the
corresponding public database sequences were chosen
over the original sequences for array inclusion. When
reverse orientation alignments were observed, both the
original contigs and public database sequences were
included. Public database sequences extending the 3' end
of the expression data-derived sequences were included in
the array design process along with the original expression
data-derived sequences, since the latter were detected
experimentally and likely represented alternatively polya-Page 3 of 12
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nificant alignments to any public database sequences
were included in their original form.
Contigs derived from the 5' EST assembly and non-polya-
denylated sequences derived from expression data were
BLASTed against sequences from RefSeq, EMBL and the 3'
portion of UTRdb [38,39] databases. Alignments with ≥
90% identity over ≥ 50% of the query sequence were
selected and processed using custom Perl scripts in order
to identify 3' extensions.
Sequence pruning and array design
All sequences were grouped and ranked according to their
origin, quality and certainty of 3' end completeness. The
300-base long 3'-terminal regions of sequences from
lower priority groupings were iteratively BLASTed against
corresponding regions of sequences from all higher prior-
ity groupings and those producing alignments with ≥ 90%
identity over ≥ 115 bp were removed. [See Additional file
1].
The design of standard 11 × 25-mer probe probesets was
carried out by Affymetrix within the 300-base region at
the 3' end of selected sequences. The subsection of this
region to which probes were actually designed is referred
to henceforth as a target sequence. Sequences were
removed from the design if creation of at least 8 probes
was not possible. All standard HG-U133 Plus 2 normali-
zation and housekeeping control probesets were included
in the design and custom versions designed within the last
300 bases were also requested.
Sequence content analysis of the Lung Cancer DSA
Sequence annotation
Lung Cancer DSA research tool sequence content was
annotated by blasting all target sequences against a series
of public databases. The databases utilized (in order of
priority) were RefSeq, human EMBL, human DDBJ and
Unigene [40]. Target sequences were blasted and the high-
est prioritized database sequence they aligned to with ≥
90% identity over ≥ 50% of their length was used for
annotation. Annotation was performed by retrieval of a
target sequence's corresponding public database accession
number and publicly available annotation information
associated with it. Where sequences did not produce a sat-
isfactory alignment to any of these databases, alignments
to the human genome were performed.
Derivation of unique content list
HG-U133 Plus 2 full sequences and probes were down-
loaded from the Affymetrix website [30]. Agilent and Illu-
mina probes were downloaded from their respective
manufacturers' websites [41,42]. Agilent and Illumina full
sequences were unavailable from the manufacturers who
recommended downloading representative sequences
from public databases based on array annotation. Array
annotation was retrieved from the manufacturers' web-
sites and public sequence accession numbers representing
the probesets on the Illumina and Agilent arrays were
used to retrieve sequences where possible. All Illumina
sequences were obtained using the Batch Entrez [43]
nucleotide retrieval function at the NCBI website. A
majority of Agilent sequences were retrieved in an identi-
cal fashion. A further subset of Agilent sequences was
extracted using predicted transcript files (release 46)
retrieved from Ensembl [44] and the DFCI's human gene
index release 17.0 [45].
The Lung Cancer DSA probesets were blasted against the
full sequences used in design of the generic arrays. Where
6 or more probes from a probeset (usually 11 probes)
aligned to the same sequence with 100% identity over
their entire length, the probeset was considered 'common'
to a generic array. Full sequences representing probesets
not considered common at this stage were extracted and
generic array probes blasted against them. For the HG-
U133 Plus 2 array, 6 or more probes from a probeset (usu-
ally 11 probes) aligned to the same sequence with 100%
identity over their entire length was considered a positive
result. Since the Agilent and Illumina platforms utilize
single probes rather than probesets, a single probe align-
ment of 100% identity across its entire length was consid-
ered a positive result. Where one or more of the 3 generic
arrays produced a positive result, the Lung Cancer DSA
probeset representing the full sequence was again consid-
ered 'common'. Thus, the 'unique' grouping represents
probesets that do not bear significant similarity to a
generic array's full sequence, nor do they show significant
similarity between their own full sequences and the
generic arrays' probes.
Gene Ontology analysis
A selection of major biological process categories relevant
to cancer studies were selected and all related biological
process GO terms retrieved using the AmiGO browser and
search engine on the Gene Ontology website [46]. The 9
major categories selected were: angiogenesis, apoptosis,
proliferation, cell-cycle control, developmental processes,
DNA repair, cell signaling, cell migration and immunol-
ogy/inflammation. 535 biological process GO terms were
retrieved and associated with the category they belonged
to. A custom Perl script was used to search the unique
Lung Cancer DSA probesets' annotations for GO terms
and associate probesets with each category for which their
annotation contained a related term. Probesets whose
annotation did not contain GO terms or contained GO
terms not associated with the major categories were classi-
fied in an "unknown" or "other" grouping respectively.
Lists of those probesets detected, differentially expressed,Page 4 of 12
(page number not for citation purposes)
BMC Medical Genomics 2008, 1:20 http://www.biomedcentral.com/1755-8794/1/20or annotating in reverse orientation to RefSeq sequences
were created and used by the script to further subdivide
the 9 categories.
Technical assessment experiment
Tissue collection and RNA isolation
Frozen pairs of lung squamous cell carcinoma and adja-
cent normal lung tissue originating from a single donor
were obtained from Asterand (Detroit, MI). All sample
pairs were processed immediately and under identical
conditions. All Asterand samples are collected following
written patient consent and ethical review board approval
[47].
Total RNA was isolated from frozen samples using Stat-60
(Tel Test, Friendswood, TX). Following RNA isolation, the
frozen samples were subjected to DNase treatment using
the RNase-free DNase set (Qiagen) and then purified and
concentrated using the RNeasy MinElute Cleanup Kit
(Qiagen).
Target preparation, hybridization and Affymetrix GeneChip analysis
Target preparation was performed using the WT-Ovation™
RNA Amplification System (NuGEN Technologies, San
Carlos, CA). To ensure sufficient cDNA yield, ten replicate
amplifications were performed from each starting RNA
sample using 10 ng and 50 ng of total RNA from the fro-
zen samples. The amplified cDNA was fragmented and
labeled using the FL-Ovation™ cDNA Biotin Module V2.
Randomly selected pairs of fragmented cDNA samples
were pooled and 5 μg of cDNA hybridized to Lung Cancer
DSA arrays. Arrays were then washed and stained using
Affymetrix fluidics script EukGE-WS2-v4 and scanned
using the Affymetrix GeneChip Scanner 3000 for data
acquisition. All kits, reagents and equipment were used
according to manufacturer's instructions.
The yield of total RNA and amplified cDNA was assessed
using the Eppendorf Biophotometer. The quality of the
total RNA, cDNA and fragmented targets was determined
using the Agilent 2100 Bioanalyser according to manufac-
turer's instructions.
Gene expression analysis
Quality of samples and data was assessed on the basis of
parameters extracted from GCOS report (RPT) files and
detection of array outliers performed with the dChip soft-
ware [48] Version 2007.
Gene expression analysis was carried out with dChip soft-
ware and Matlab® (Version 2007a) with Bioinformatics
and Statistics Toolboxes. Data pre-processing was carried
out with dChip Invariant Set Normalization and PM-only
Model Based Expression summarization. The MAS5.0
algorithm with the default significance threshold (α =
0.05) was used to define present calls for probesets.
Coefficient of variance and correlation coefficient were
calculated only for probesets consistently called present in
all tumor and all normal replicates. Coefficient of varia-
tion for replicates in normal and tumor groups was calcu-
lated as a median value of the ratios of standard deviation
of intensity to the median intensity for all qualifying
probesets across replicates, and multiplied by 100 to pro-
duce the Coefficient of Variance. The correlation coeffi-
cient was calculated as the average value of the Spearman
correlation coefficients for all pairs of replicates within
normal and tumor groups. Autocorrelations were
excluded.
Selection of differentially expressed probesets (DEPS)
between the replicates of tumor and normal samples was
performed using the following criteria:
(1) Fold change (FC) filter: |log2(FC)| > log2(1 + 3*μCV)
= log2(1.2), where μCV is the median of the coefficients of
variation of expression intensity (CVi) for all probesets on
the array. CVi for each probeset was calculated as a ratio of
the pooled standard deviation of probeset intensity to the
median probeset intensity:
 , where μi is the median
probeset intensity for all replicates in both normal and
tumor groups; σi1 and σi2 are the standard deviations of
probeset intensity and n1 and n2 are the numbers of repli-
cates in normal and tumor groups, respectively.
(2) Low expression difference filter: |E - B| > [AvBg + 3*
σ(Bg)] = 38, where E and B are average expression inten-
sities in tumor and normal groups, respectively; AvBg is
the average background value for all profiles in tumor and
normal groups; and σ(Bg) is standard deviation of back-
ground values for all profiles in tumor and normal
groups.
(3) Present call filter: present in all replicates of an over-
expressed group (tumor or normal).
(4) Student's t-test filter: p < 0.001.
Perl and Matlab scripts used for data processing and anal-
ysis are available from the authors upon request.
CVi i
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σ σPage 5 of 12
(page number not for citation purposes)
BMC Medical Genomics 2008, 1:20 http://www.biomedcentral.com/1755-8794/1/20Results and Discussion
Generation of the Lung Cancer DSA
The transcriptome of NSCLC and normal lung tissue was
characterized using three sources of information 
(Figure 1)
(i) In-house and publicly available sequence data
Non-normalized cDNA libraries were generated and
sequenced separately for NSCLC tumor and normal lung
tissue. 403,494 expressed sequence tags (ESTs) were gen-
erated in-house from the tumor libraries and supple-
mented by 336,280 human lung ESTs from 291 publicly
available libraries in order to optimally represent the
diversity of the NSCLC transcriptome. These 3' and 5'
derived sequences were included in the array design proc-
ess along with 166,411 3' ESTs generated in-house from
the normal lung library. The 3' and 5' derived sequences
were filtered and assembled separately producing a total
of 41,497 contigs and 89,695 singlet sequences for the
array design process.
(ii)Gene expression data derived from in-house experiments and 
public databases
Data from 70 publicly available and in-house generated
lung normal and cancer microarray profiles were analyzed
in order to identify transcripts reliably detected as
expressed in lung tissue. As a result, 17,128 polyade-
nylated and 21,687 non-polyadenylated publicly availa-
ble sequences corresponding to the detected probesets
were selected for the array design process.
(iii) Literature mining
In addition to the above empirical approaches we per-
formed literature mining, which resulted in the inclusion
of 1,445 full-length mRNA sequences previously impli-
cated in lung cancer. This grouping contained both
known and putative transcripts. Analysis revealed that
96% of these had already been identified by the empirical
means described, demonstrating the comprehensive
nature of the approach. Due to their potential impor-
tance, the literature-derived sequences were retained as a
distinct grouping in order that they be excluded from
pruning. We also included their computationally derived
antisense complements.
The sequence data obtained from these approaches was
assembled and analyzed for internal priming, alternative
polyadenylation and potential 3' termini extension of 5'
sequences
Identification of alternative polyadenylation
The advantage of 3' sequencing is that it allows the capture
of genuine 3' sequence termini and the detection of alter-
native polyadenylation. This important information is
usually lost as a result of applying conventional sequence
assembly methods. In order to prevent this loss, contigs
Schematic representation of the generation of the Lung Cancer DSA research tool showing the parallel approaches (in-house sequencing, public seque ce databas  mini g and gene expression profiling) used to characterize the NSCLC transcriptome, from wh h the Lu g Ca r DSA was desi nedFig re 1
Schematic representation of the generation of the Lung Cancer DSA research tool showing the parallel 
approaches (in-house sequencing, public sequence database mining and gene expression profiling) used to 
characterize the NSCLC transcriptome, from which the Lung Cancer DSA was designed.Page 6 of 12
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a custom computational pipeline, for potential instances
of alternative polyadenylation. 732 such instances were
identified and alternatively polyadenylated forms of such
contigs were also included in the array design process. The
combined approach of 3' sequencing and computational
identification of alternative polyadenylation ensured that
the final array represented all detectable 3' splice/polyade-
nylation variants identified by our methods. This group of
sequences potentially contains tissue or disease specific
variants vital to focused NSCLC studies and not repre-
sented on generic microarrays.
Sequence pruning and array design
All selected sequences were grouped and ranked according
to their origin, quality and certainty of 3' end complete-
ness and pruned against one another to remove redun-
dancy [See Additional file 2]. The literature-derived lung
cancer related sequences were given the highest priority
and were not pruned. The resulting non-redundant set of
sequences was considered to represent the NSCLC tran-
scriptome and 3' target regions of these sequences were
submitted to Affymetrix for probe design and array man-
ufacture.
Sequence content assessment of the Lung Cancer DSA
The resulting Lung Cancer DSA research tool contains
59,927 probesets representing transcripts expressed in
NSCLC and normal lung tissue, and a further 489 normal-
ization, hybridization and housekeeping control
probesets, including all 162 standard Affymetrix HG-
U133 Plus 2 GeneChip (HG-U133 Plus 2) controls [See
Additional file 2]. The majority of the array content (53%)
was derived from cDNA sequencing (Figure 2A). This was
followed by expression data-derived sequences (32%)
and public database sequences identified while extending
3' termini of 5' EST assembly and expression data derived
sequences (10%). The remaining 5% of the array content
consists of literature-derived sequences previously impli-
cated in lung cancer and their antisense complements.
Analysis of the array content demonstrated that 42% of
transcripts on the Lung Cancer DSA research tool have no
significant homology with sequences from NCBI's Refer-
ence Sequence Database, RefSeq in either orientation and
13% represent sequences transcribed in antisense orienta-
tion to annotated RefSeq transcripts (Figure 2B). Further
analysis identified a total of 6,206 transcripts, represented
on the Lung Cancer DSA research tool in both the sense
and corresponding antisense orientation.
Comparison of the content of the Lung Cancer DSA
research tool with the 3 leading commercial human arrays
demonstrated that there were 18,635 transcripts, 27,777
transcripts and 31,211 transcripts not detectable by the
Affymetrix HG U-133 Plus2 array, Agilent Whole Human
Genome Array and the Illumina Human 6 array respec-
tively (Table 1). In addition, a core set of 15,541 Lung
Cancer DSA research tool unique transcripts were not
A) Origin of the content of the completed Lung Cancer DSA, showing that th  majority of the array content (53%) was der ved from sequencing data, fol owed by expression profilin  derived da a (32%)Figur  2
A) Origin of the content of the completed Lung Cancer 
DSA, showing that the majority of the array content (53%) 
was derived from sequencing data, followed by expression 
profiling derived data (32%). B) Comparison of the Lung 
Cancer DSA sequence content with the RefSeq mRNA data-
base.
Table 1: Comparison of the Lung Cancer DSA content with the Affymetrix Plus2, Agilent Whole Human Genome and Illumina 
Human 6 arrays.
Commercial gene expression microarray Lung Cancer DSA research tool unique transcripts
Affymetrix HG-U133 Plus2 array 18635
Agilent Whole Human Genome array 27777
Illumina Human 6 array 31211
Comparison with content of 3 arrays combined 15541Page 7 of 12
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strating the increased coverage of the lung transcriptome
by the Lung Cancer DSA research tools.
Examination of these 15,541 transcripts revealed that 4%
(647) had significant homology with RefSeq transcripts,
40% (6,157) had significant homology with RefSeq in
antisense orientation and 21% (3,302) and 16% (2,420)
had significant homology with EMBL in sense and anti-
sense orientations respectively (Table 2). For the remain-
ing transcripts 16% (2,514) had significant homology
with Unigene and 2% (353) with the human genome,
while 148 demonstrated no homology with any of the
databases. The large number of antisense sequences
included within this grouping is notable. Antisense tran-
scription is a subject which is now receiving increased
attention in scientific literature and these transcripts are
underrepresented on current generic microarrays. Anti-
sense transcription has been associated with many impor-
tant regulatory functions and its consideration when
designing the Lung Cancer DSA research tool has ensured
inclusion of probesets potentially vital in applications
such as classifier generation.
Technical assessment experiment
To assess the biological relevance of the content of the
Lung Cancer DSA research tool, five technical replicates of
two RNAs extracted from a single patient matched normal
and NSCLC frozen tissue were profiled on the arrays. The
results demonstrated that in total 35,625 transcripts were
consistently detected by the Lung Cancer DSA research
tool as being expressed in either the normal or tumor tis-
sue. These included 6398 (41%) of the Lung Cancer DSA
research tool unique transcripts with 155 RefSeq, 982
human EMBL and 1,021 Unigene transcripts being
detected in the sense orientation (Table 2). In addition we
observed significant detection of antisense transcripts,
with 3,437 (55%) of the RefSeq sense-antisense (SA) tran-
script pairs detected as being expressed in either the nor-
mal or tumor tissue.
Comparing the transcript expression levels between the
normal and tumor lung tissue identified 2,148 of the
unique transcripts as being differentially expressed and
thus potentially important to the underlying biology of
this disease (Table 2). These included RefSeq sense tran-
scripts to predicted proteins with associated functions in
processes such as apoptosis, cell cycle control, cell prolif-
eration and DNA damage repair [See Additional file 3]. In
addition there was extensive differential expression of
sense transcripts with homology to the coding DNA
sequence (cds) of known genes and antisense transcripts
(Table 2).
To further investigate the relevance of the detected and
differentially expressed unique content to the biology of
NSCLC, the annotation associated with these transcripts
was assessed by Gene Ontology mining for implicated
roles in processes linked to cancer. This clearly demon-
strated association of these transcripts with the main cel-
lular processes linked to cancer, including proliferation,
apoptosis and DNA damage repair (Table 3). An example
of one such group, DNA repair, is given in Table 4 where
21 antisense transcripts differentially expressed between
the normal and tumor samples were identified.
Conclusion
The recently published results of the ENCODE consor-
tium's pilot project indicate that the majority of the
human genome is transcribed and that a minority of tran-
scriptional activity leads directly to protein production
[19]. This and other evidence has highlighted the com-
plexity of the transcriptome and the need for better tools
to study it [23,49]. Since studying the entire human tran-
scriptome is not possible using current technologies, we
propose a practical alternative of developing a range of
microarray research tools capable of interrogating tran-
scriptomes of individual disease settings
Given the importance of NSCLC as a disease and the
extent of genomics research in this area, we have endeav-
oured to characterise the transcriptome of NSCLC by
means of in-house sequencing, mining of public sequence
databases, gene expression profiling and literature min-
ing. This information was used to design the Lung Cancer
DSA representing ~60,000 transcripts empirically shown
to be expressed in NSCLC and normal lung tissue
Table 2: Experimental detection of the Lung Cancer DSA unique content in matched normal tumor lung tissue.
Annotation database # Unique transcripts # Detected unique transcripts # Differentially expressed unique transcripts
RefSeq 647 155 43
Antisense to RefSeq 6157 3377 1301
EMBL 3302 982 274
Antisense to EMBL 2420 852 256
Unigene 2514 1021 306
Genome 353 9 4
Unannotated 148 2 0Page 8 of 12
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most commonly used generic gene expression microar-
rays, a significant proportion of the array is unique in rela-
tion to each array as shown in Table 1. 15,541 Lung
Cancer DSA research tool transcripts are not detectable by
the Affymetrix HG U-133 Plus2 array, the Agilent Whole
Human Genome Array or the Illumina Human 6 array,
clearly demonstrating that the transcriptome of NSCLC is
better represented by the Lung Cancer DSA research tool.
This enables researchers using the Lung Cancer DSA to
interrogate over 15,000 additional transcripts, all relevant
to NSCLC.
The technical assessment experiment shows that data gen-
erated by the Lung Cancer DSA is highly reproducible and
exhibits extremely good correlation and low coefficient of
variance, similar to those obtained from generic Affyme-
trix arrays in our own [See Additional file 4] and in previ-
ously published studies [50].
A large part of the Lung Cancer DSA content is not repre-
sented in the RefSeq database of well annotated mRNAs.
Importantly, 46.3% of the non-RefSeq transcripts were
reliably detected in the technical assessment experiment
using samples taken from a single patient.
An even greater proportion (58%) of transcripts antisense
to annotated RefSeq sequences were also consistently
detected, further highlighting the magnitude of antisense
transcription that is not fully annotated or understood.
Table 3: Gene Ontology mining of the experimentally detected unique Lung DSA transcripts associated annotation.
GO process Unique detected 
transcripts







Angiogenesis 26 18 13 9
Apoptosis 311 186 112 77
DNA repair 119 65 32 21
Cell migration 71 34 27 17
Proliferation 287 186 117 85
Immunology/Inflammation 196 118 83 55
Developmental genes 12 8 10 7
Cell cycle control 384 239 139 111
Cell Signaling Pathway 55 40 33 25
Other 3851 2270 1382 910
Unknown 2461 820 770 293
Table 4: RefSeq antisense transcripts differentially expressed between the normal and tumor lung tissue, from the unique Lung Cancer 
DSA research tool content.
Target accession number Probe ID Database Orientation Gene symbol Fold change P value
NM_000546 LCHPRC.1183_s_at RefSeq Antisense TP53 2.12 0.000147
NM_000059 LCHPRC.7_at RefSeq Antisense BRCA2 2.73 0.000056
NM_130398 LCMXR.3025C1_at RefSeq Antisense EXO1 4.22 0.000566
NM_002431 LCHPRC.358_at RefSeq Antisense MNAT1 1.89 0.000006
NM_078468 LC3P.8284C2_at RefSeq Antisense BCCIP 1.80 0.00001
NM_002129 LCSS.2843_at RefSeq Antisense HMGB2 1.66 0.000061
NM_007192 LCMXR.12622C1_at RefSeq Antisense SUPT16H 1.82 0.000001
NM_001239 LCHPRC.1335_at RefSeq Antisense CCNH -1.95 0.000007
NM_004219 LCMXR.7995C1_at RefSeq Antisense PTTG1 3.7 0.000000
NM_001274 LCHPRC.250_at RefSeq Antisense CHEK1 6.63 0.000013
NM_001806 LCMXR.17153C1_at RefSeq Antisense CEBPG 2.82 0.000123
NM_000057 LCHPRC.1353_at RefSeq Antisense BLM 1.68 0.000804
NM_021117 LCMXR.1610C3_at RefSeq Antisense CRY2 -5.89 0.000007
NM_001067 LCHPRC.222_at RefSeq Antisense TOP2A 10.81 0.000002
NM_000123 LCMXR.7050C1_at RefSeq Antisense ERCC5 -1.99 0.000014
NM_014502 LCMXR.187C1_at RefSeq Antisense PRPF19 1.82 0.000085
NM_021117 LCMXR.1610C1_s_at RefSeq Antisense CRY2 -3.4 0.000341
NM_001274 LCMXR.7773C1_at RefSeq Antisense CHEK1 7.07 0.000022
NM_002945 LCMXR.7467C1_at RefSeq Antisense RPA1 1.7 0.00008
NM_007027 LCMXR.5891C1_at RefSeq Antisense TOPBP1 4.74 0.000004
NM_152221 LCMXR.392C1_at RefSeq Antisense CSNK1E 1.57 0.000041Page 9 of 12
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were 2667 and 5880 sense-antisense (SA) pairs tran-
scribed from the human genome respectively. Our results
from the analysis of a single tissue type and disease setting
would suggest that the total number of SA pairs in the
human transcriptome may be considerably higher.
Interestingly, based on the hypothesis that antisense tran-
scription is the norm rather than the exception, we
included in the array design 1143 sequences artificially
created as antisense to those derived by literature and
pathway mining. Of these 1143 sequences, 412 were con-
sistently detected in the technical assessment experiment
with 198 of these being differentially expressed, lending
weight to the growing body of evidence that antisense
transcription is extremely widespread [51,53-55].
Gene ontology mining served to demonstrate the poten-
tial importance of the unique Lung Cancer DSA content.
Major cancer related GO process categories were highly
represented by uniquely detected or differentially
expressed transcripts and significant proportions of these
transcripts were shown to bear antisense homology to
well characterised RefSeq sequences (Table 4). 21 anti-
sense transcripts linked to DNA damage repair were differ-
entially expressed between the normal and tumor
samples. These included antisense transcripts homolo-
gous to BRCA2, CHEK1 and TP53. Interestingly, TP53
antisense mRNA has previously been identified in human
cells [51]. Antisense sequences are believed to function in
gene regulation by modulating sense mRNA transcription,
maturation, transport, stability and translation. The exten-
sive detection of differentially expressed antisense tran-
scripts between the normal and tumor tissue supports a
role for these sequences in NSCLC pathogenesis. Moreo-
ver, a conventional generic microarray would not have
detected these potentially important transcripts.
The Lung Cancer DSA research tool presented in this com-
munication represents a powerful and practical tool for
both basic and translational research that better reflects
the complexity of the NSCLC transcriptome than com-
monly used microarrays. We believe it to have applica-
tions in areas such as pathway analysis, biomarker and
drug target discovery and multivariate prognostic and pre-
dictive classifier generation. Its disease-focused design
and novel, relevant content could ultimately lead to a bet-
ter understanding of the underlying biology of NSCLC.
In addition, this methodology serves as a template for the
development of other disease transcriptome focused
microarrays, including non-neoplastic diseases.
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